By Peter G. Traber, M.D. on April 21, 2016 I suppose it’s natural to assume that only overweight people get fatty liver disease (and NASH), but one thing I have...
Read More
By Peter G. Traber, M.D. on March 24, 2016 You may have seen Newsweek’s recent article on the growing impact of NASH, NASH Is the 21st Century’s Looming Health Threat....
Read More
By Peter G. Traber, M.D. on March 17, 2016 We often talk about how Galectin Therapeutics’ proprietary compound, GR-MD-02, is protected by a strong intellectual property portfolio. I thought it...
Read More
By Peter G. Traber, M.D. on February 22, 2016 Everyone has had the experience of having their blood pressure taken and knows the importance of a normal reading for good...
Read More
By Peter G. Traber, M.D. on February 11, 2016 I wrote recently about the need for non-invasive tests to replace liver biopsies in the evaluation of liver fibrosis due to...
Read More
By Peter G. Traber, M.D. on February 3, 2016 Are you one of the nearly 40% of Americans classified as obese or are you overweight and inexorably headed towards obesity? ...
Read More
By Peter G. Traber, M.D. on January 28, 2016 I wrote recently about why we rely on liver biopsies for the diagnosis of NASH and liver fibrosis and the need for...
Read More
By Peter G. Traber, M.D. on January 20, 2016 Several of my past CEO Perspectives have touched on the need for a non-invasive test in diagnosing and following treatment of fatty...
Read More
By Galectin Therapeutics. on January 7, 2016 The many accomplishments at Galectin Therapeutics during 2015 ranged from incremental progress touching every aspect of our business to significant advancements with GR-MD-02. Importantly,...
Read More
By Peter G. Traber, M.D. on December 7, 2015 In June 2015 Galectin Therapeutics initiated a clinical trial to determine if our investigational drug GR-MD-02 can successfully treat patients with...
Read More